BridgeMD
New treatment option for Mild Cognitive Impairment (MCI)
Official title EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069
ClinicalTrials.gov ID: NCT06657274
What this study is testing
- What it's testing
- The increase in life expectancy in recent decades has led to a large number of people living into old age and an increased risk of developing Chronic Neurological Diseases (CNDs) such as neurodegenerative diseases. A higher cumulative risk of dementia has been largely demonstrated in Mild Cognitive Impairment (MCI) and Subjective Cognitive Complaints (SCCs) subjects and in Parkinson's Disease (PD) patients, as compared to the general population.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 85
You may be able to join if
- Diagnosis of PD (Hoehn \& Yahr\<3); MCI (with CDR scale≤0.5, MMSE ≥24), and SCC (Subjective Cognitive Complaints);
- Montreal Cognitive Assessment (MoCA) corrected score ≥17.36
- Education ≥ 5 years
- Age eligible for the study: 18≤age≤85
- Native Italian speakers
You likely can't join if
- Presence of any medical or psychiatric illness that could interfere with completing assessments;
- Presence of any medical condition representing a contraindication to TMS.
See the full eligibility criteria
- Diagnosis of PD (Hoehn \& Yahr\<3); MCI (with CDR scale≤0.5, MMSE ≥24), and SCC (Subjective Cognitive Complaints);
- Montreal Cognitive Assessment (MoCA) corrected score ≥17.36
- Education ≥ 5 years
- Age eligible for the study: 18≤age≤85
- Native Italian speakers
- Absence of marked hearing/visual impairment
- All of the people will have normal or corrected-to-normal vision.
- Agreement to participate by signing the informed consent form
- Availability of a caregiver/study partner able to support the participant
- No rehabilitation program in place at the time of enrolment or in the last 3 months before enrolment
- Stable drug treatment (last 3 months), if any
- Presence of any medical or psychiatric illness that could interfere with completing assessments;
- Presence of any medical condition representing a contraindication to TMS.
The study team makes the final eligibility decision.
Where it's taking place
- Brescia, IT, Italy
- Messina, IT, Italy
- Milan, IT, Italy
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Brescia, IT, Italy; Messina, IT, Italy; Milan, IT, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.